Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enlimomab

Next Previous
Drug Profile

Enlimomab

Alternative Names: BIRR 0001; BIRR 1; Murine anti-CD54 monoclonal antibody; Murine anti-ICAM-1 monoclonal antibody; R6 5 D6; R6.5; RR1; RR1/1

Latest Information Update: 18 Dec 2001

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Autoimmune disorders; Burns; Diabetes mellitus; Graft-versus-host disease; Intracranial thrombosis; Liver transplant rejection; Myocardial ischaemia; Renal transplant rejection; Rheumatoid arthritis; Stroke

Most Recent Events

  • 18 Dec 2001 A study has been added to the adverse events and Neurological Disorders therapeutic trials sections
  • 10 May 1999 Results of a clinical study were added to the adverse events and therapeutic trials sections
  • 03 Feb 1999 A study has been added to the Neurological disorders pharmacodynamics section
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top